Immutep Ltd has released a press release.
Immutep: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
Later from Immutep
- Trading Halt
- Suspension from Quotation
- Reinstatement to Quotation
- TACTI-004 to be discontinued following futility analysis
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep